176 related articles for article (PubMed ID: 36259353)
1. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
[TBL] [Abstract][Full Text] [Related]
2. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
5. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Feb; ():. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
9. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
11. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S; Wang J; Cheng Y; Mok T; Chang J; Zhang L; Feng J; Tu HY; Wu L; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Ying K; Zhong H; Poddubskaya E; Soo RA; Chia YH; Li A; Li A; Wu YL
Lung Cancer; 2021 Feb; 152():7-14. PubMed ID: 33321441
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
14. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
16. Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma.
Peterse EFP; Verburg-Baltussen EJM; Stewart A; Liu FF; Parker C; Treur M; Malcolm B; Klijn SL
Pharmacoecon Open; 2023 Nov; 7(6):941-950. PubMed ID: 37651087
[TBL] [Abstract][Full Text] [Related]
17. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
18. An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.
Vickers A
Med Decis Making; 2019 Nov; 39(8):926-938. PubMed ID: 31631772
[No Abstract] [Full Text] [Related]
19. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Gibson E; Koblbauer I; Begum N; Dranitsaris G; Liew D; McEwan P; Tahami Monfared AA; Yuan Y; Juarez-Garcia A; Tyas D; Lees M
Pharmacoeconomics; 2017 Dec; 35(12):1257-1270. PubMed ID: 28866758
[TBL] [Abstract][Full Text] [Related]
20. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]